newswire, breaking biotechnology and pharma news

Wednesday, March 2, 2016

Denis Corin, President and CEO of Q BioMed Inc. (OTCQB: QBIO) Talks to Daniel Levine of the Bio Report

Save Cancel

Denis Corin, President and CEO of Q BioMed Inc. (OTCQB: QBIO) Talks to Daniel Levine of the Bio Report

Pharma Bro, Price Controls, and the Quest to Balance Innovation with Affordability; Perspective on the fallout from Shkreli

March 2, 2016 - a global digital media source covering leading sectors including biotech stocks profiles the following biotech interview. Denis Corin, President and CEO of Q BioMed Inc. (OTCQB: QBIO) talks with Daniel Levine of the Bio Report about some recent controversial topics in the sector. 

The Bio Report Podcast Overview:
The embattled pharma executive Martin Shkreli, whether intentional or not, has ignited a long smoldering public policy discussion about the pricing of pharmaceuticals. As there are growing calls for steps to restrain drug prices, there are also industry concerns about the effect such actions would have on the ability to attract investment and pursue the development of high-risk, innovative therapies. We spoke to Denis Corin, CEO of Q BioMed, an acceleration and development company, for a perspective on the fallout from Shkreli, how to balance innovation with affordability, and whether he expects any lasting impacts on small drug developers.

It can also be watched at

The Bio Report podcast, hosted by veteran journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

About Q BioMed Inc. (OTCQB: QBIO)
Q BioMed Inc. ("Q") is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

About - Big Ideas for Global Investors - digital media global news source, PR and social media in leading sectors including Biotech.

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: Disclosure: QBIO has retained for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

800 665 0411

No comments:

Post a Comment